Oxabicyclo [2.2.2] acid GPR120 modulators

Abstract

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

What is claimed is: 
     
       1. A compound of Formula (I): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
 X is independently CH 2 O or OCH 2 ; 
 L 1  is independently a hydrocarbon linker substituted with 0-2 R c , a hydrocarbon-heteroatom linker substituted with 0-2 R c , or —(CH 2 ) 1-3 —(C 3-4  cycloalkyl substituted with 0-2 R c )—(CH 2 ) 0-2 —; wherein said hydrocarbon linker has one to six carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to four carbon atoms and one group selected from O, CO, S(O) p , NH, N(C 1-4  alkyl), CONH, NHCO and NHCO 2 ; 
 R 1  is independently selected from: C 6-10  carbocycle and a 5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR b , O, and S(O) p ; wherein said carbocycle and heterocycle are substituted with 0-4 R 3  and R 4 ; 
 R 2  independently selected from: OH, CO 2 H, —CONHSO 2 R e , and —CONH—(CH 2 ) 0-3 -(5-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR b , O, and S(O) p ;); 
 R 3 , at each occurrence, is independently selected from: halogen, C 1-6  alkyl, C 1-4  alkoxy, C 1-4  alkylthio, C 1-4  haloalkyl, C 1-4  haloalkoxy, C 1-4  haloalkylthio, and NO 2 ; 
 R 4  is independently -L 2 -R 5 ; 
 L 2  is independently selected from: O, S, CH 2 , C(═O), and —OSO 2 ; 
 R 5  is independently selected from: C 1-6  alkyl, C 2-6  alkenyl, C 1-6  haloalkyl, —(CH 2 ) n —C 3-6  carbocycle and a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR b , O, and S(O) p ; wherein each ring moiety is substituted with 0-2 R a ; 
 R a , at each occurrence, is independently selected from: halogen, C 1-4  alkyl, C 1-4  alkoxy, and C 1-4  haloalkyl; 
 R b , at each occurrence, is independently selected from: H, C 1-4  alkyl, and —(CH 2 ) 0-2 -(phenyl substituted with 0-3 R d ); 
 R c , at each occurrence, is independently selected from: halogen, OH, C 1-4  alkyl, C 1-4  haloalkyl, and C 1-4  alkyoxy; 
 R d , at each occurrence, is independently selected from: halogen, C 1-4  alkyl, C 1-4  alkoxy, and C 1-4  haloalkyl; 
 R e  is independently selected from: C 1-4  alkyl and phenyl; 
 p is, independently at each occurrence, selected from 0, 1, and 2; and 
 n is, independently at each occurrence, selected from 0, 1, and 2. 
 
     
     
       2. A compound according to  claim 1 , wherein:
 L 1  is independently a hydrocarbon linker substituted with 0-1 R c , a hydrocarbon-heteroatom linker substituted with 0-1 R c , or —(CH 2 ) 1-2 —(C 3-4  cycloalkyl substituted with 0-1 R c )—(CH 2 ) 0-1 —; wherein said hydrocarbon linker has one to six carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to four carbon atoms and one group selected from O, CO, S(O) p , CONH, and NHCO 2 ; 
 R 1  is independently selected from: phenyl, indanyl, naphthyl, and a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR b , O, and S(O) p ; wherein each ring moiety substituted with 0-4 R 3− R 4 ; and 
 L 2  is independently selected from: O, S, CH 2 , and —OSO 2 ; 
 R 5  is independently selected from: C 1-6  alkyl, C 2-6  alkenyl, C 1-4  haloalkyl, tetrahydropyranyl, —(CH 2 ) n —(C 3-6  carbocycle substituted with 0-2 R a ), and pyridyl substituted with 0-1 R a . 
 
     
     
       3. A compound of Formula (II): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
 X is independently CH 2 O or OCH 2 ; 
 L 1  is independently a hydrocarbon linker substituted with 0-1 OH, a hydrocarbon-heteroatom linker or —(CH 2 ) 1-2 -(cyclopropyl)-(CH 2 ) 0-1 —; wherein said hydrocarbon linker has one to five carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to five carbon atoms and may be straight or branched, and has one to three carbon atoms and one group selected from O, CONH and NHCO 2 ; 
 R 3 , at each occurrence, is independently selected from: halogen, CF 3 , OCF 3 , SCF 3 , NO 2 , C 1-4  alkyl, C 1-4  alkoxy, and C 1-4  alkylthio; 
 R 4  is independently -L 2 -R 5 ; 
 L 2  is independently: O or S; 
 R 5  is independently selected from: —(CH 2 ) 0-1 —C 4-6  cycloalkyl, C 5-6  cycloalkenyl, tetrahydropyranyl, pyridyl substituted with 0-2 R a , and -L 3 -(phenyl substituted with 0-2 R a ); and 
 R a , at each occurrence, is independently selected from: halogen, C 1-4  alkyl and C 1-4  alkoxy. 
 
     
     
       4. A compound according to  claim 3 , wherein:
 L 1  is independently selected from: (CH 2 ) 4 , CH 2 CH 2 OCH 2 , CH 2 OCH 2 CH 2 , CH 2 CH 2 CH 2 OCH 2 , CH 2 CH 2 CH═CH, CH 2 CH═CHCH 2 , CH 2 CONHCH 2 , CH 2 NHCO 2 CH 2 , 
 
       
         
           
           
               
               
           
         
          and 
         R 4  is independently selected from: cyclopentenyl, —O—CH 2 -cyclobutyl, —O-(CH 2 ) 0-1 -cyclohexyl, —O-tetrahydropyranyl, —O-pyridyl, and -L 3 -(CH 2 ) 0-1 -(phenyl substituted with 0-2 R a ). 
       
     
     
       5. A compound according to  claim 4 , wherein the compound is of Formula (III): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
 X is independently CH 2 O or OCH 2 ; 
 L 1  is independently selected from: (CH 2 ) 4 , CH 2 CH 2 OCH 2 , CH 2 OCH 2 CH 2 , CH 2 CH 2 CH 2 OCH 2 , CH 2 CH 2 CH═CH, CH 2 CH═CHCH 2 , CH 2 CONHCH 2 , CH 2 NHCO 2 CH 2 , 
 
       
         
           
           
               
               
           
         
         L 2  is independently O or S; 
         R 3  is independently halogen; 
         R a , at each occurrence, is independently selected from: halogen, C 1-4  alkyl and C 1-4  alkoxy. 
       
     
     
       6. A compound according to  claim 5 , wherein:
 L 1  is independently selected from: (CH 2 ) 4 , CH 2 CH 2 OCH 2 , CH 2 OCH 2 CH 2 , CH 2 CH 2 CH 2 OCH 2 , CH 2 CH 2 CH═CH, CH 2 CH═CHCH 2 , 
 
       
         
           
           
               
               
           
         
          and 
         L 2  is O. 
       
     
     
       7. A compound selected from the following or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,
 3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propanoic acid; 
 3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propanoic acid; 
 5-(1-(3-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanoic acid; 
 5-(1-(2-methyl-4-phenylthiazol-5-yl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanoic acid; 
 3-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methoxy)propanoic acid; 
 2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-isopropoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(cyclohexyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-isobutoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 5-(1-(3-(tetrahydro-2H-pyran-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanoic acid; 
 (E)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pent-2-enoic acid; 
 2-(3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propoxy)acetic acid; 
 trans-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 (1S,2S)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 (1R,2R)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 2-(2-((1-((3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methyl)cyclopropyl)acetic acid (trans); 
 2-((1R,2R)-2-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl) methyl)cyclopropyl)acetic acid; 
 2-((1S,2S)-2-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl) methyl)cyclopropyl)acetic acid; 
 2-(2-(1-(3-(2-methylallyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(2-methylprop-1-enyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(pyridin-3-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid, TFA salt; 
 2-(2-(1-(3-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-cyclopentenylphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)-N-(phenylsulfonyl)pentanamide; 
 N-(methylsulfonyl)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanamide; 
 2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)acetamido)acetic acid; 
 2-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methylcarbamoyloxy)acetic acid; 
 3-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methylsulfonyl)propanoic acid; 
 3-((4-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-1-yl)methoxy)propanoic acid; 
 2-(2-(4-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 cis-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid (racemic); 
 3-methoxy-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanoic acid; 
 (E)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pent-3-enoic acid; 
 (Z)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pent-2-enoic acid; 
 2-(2-(1-(3-fluoro-5-isobutoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(2-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(phenylthio)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(4-chlorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(p-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(m-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3-chlorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3-cyanophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(trifluoromethylsulfonyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(trifluoromethyl)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-benzylphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(cyclobutylmethoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(cyclohexylmethoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(pentan-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid (racemate); 
 2-(2-(1-(3-fluoro-5-(2,2,2-trifluoroethoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 4-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)butane-1,2-diol; 
 4-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)butan-1-ol; 
 5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentane-1,2-diol; 
 S-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentane-1,2-diol and; 
 R-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentane-1,2-diol; 
 2-(2-(1-(3-(tetrahydro-2H-pyran-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 N-((1H-1,2,4-triazol-5-yl)methyl)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan -4-yl)ethyl)cyclopropanecarboxamide; 
 2-(2-(1-(3-fluoro-5-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 2-(2-(1-(3-fluoro-5-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 2-(2-(1-(3-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4 yl)ethyl)cyclopropanecarboxylic acid; 
 2-(2-(1-(3-isobutoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid (single enantiomer); 
 2-(2-(1-(3-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid (single enantiomer); 
 N-((1H-1,2,4-triazol-5-yl)methyl)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan -4-yl)ethyl)cyclopropanecarboxamide; 
 N-ethyl-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxamide; 
 2-(2-(1-(3-(3-hydroxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 (1R,2R)-2-(2-(1-(3-(4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 (1R,2R)-2-(2-(1-(3-(3,5-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 (1R,2R)-2-(2-(1-(3-(3,4-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 (1R,2R)-2-(2-(1-(3-(4-hydroxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 2-(2-(1-(3-(3,4-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3,5-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2(2(1(3(3fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2(2(1(3(4fluoro-3-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3,4-difluorophenoxy)-5-fluorophenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(4-fluoro-3-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(p-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(3-fluoro -5-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(4-fluoro-3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(4-fluoro-3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(4-fluoro-3-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(4-fluoro-3-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-methoxy-5-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3,4-difluorophenoxy)-5-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(4-fluorophenoxy)-5-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3-fluoro-4-methylphenoxy)-5-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-fluoro-5-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)-N-hydroxyacetamide; 
 2-(2-(1-(3,4-difluoro-5-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)oxy)methyl)cyclopropanecarboxylic acid; 
 trans-2-(((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methoxy)methyl)cyclopropanecarboxylic acid; 
 2-(2-(4-(3-(3-fluoro-4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(3-fluoro-4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(4-fluoro-3-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(pyridin-3-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(p-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(3-cyanophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-fluoro-5-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(pyridin-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(3-(4-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-1-yl)propoxy)acetic acid; 
 2-(2-(4-(3-(cyclohexyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(4-fluoro-3-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(4-(3-(3,4-dimethylphenoxy)-4-fluorophenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2(2(4(3(4cyano-3-methylphenoxy)-4-fluorophenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(6-methylpyridin-3-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(6-(3,4-difluorophenoxy)pyridin-2-yl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 2-(2-(1-(3-(3-hydroxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; 
 (1R,R)-2-(2-(1-(3-(3-ethylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid; 
 2-(2-(1-(3-(3-ethylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; and 
 2-(3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propyl)cyclopropanecarboxylic acid. 
 
     
     
       8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of  claim 1 , or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof. 
     
     
       9. The pharmaceutical composition according to  claim 8 , further comprising one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-pancreatitis agents, lipid lowering agents, anorectic agents and appetite suppressants. 
     
     
       10. The pharmaceutical composition according to  claim 8 , further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor. 
     
     
       11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of  claim 3 . 
     
     
       12. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of  claim 7 .